Abstract
Purpose
Vascular endothelial growth factor (VEGF) is an important factor involved in angiogenesis. Many studies have reported that the expression of VEGF in breast cancer is an unfavorable prognostic factor. However, there are few studies that have analyzed blood VEGF levels because most used serum VEGF, generally thought to originate from platelets. We measured plasma VEGF levels, which evaluate the level of tumor-derived VEGF, in various breast diseases.
Method
We analyzed 15 patients with benign breast disease, 187 patients with primary breast cancer, 32 patients with no postoperative recurrence, and 56 patients with recurrence. Plasma VEGF levels were measured by ELISA.
Results
Plasma VEGF levels were higher in malignant than in benign breast disease, and were also high in patients with recurrence or distant metastasis. In primary cases, higher VEGF levels were clearly correlated with menopause and overexpression of p53, and postmenopausal patients with high levels had a significantly lower disease-free survival rate.
Conclusion
These results suggest that plasma VEGF levels in breast cancer have a clinical significance in that they are associated with the extent or metastasis of malignant lesions and are involved in angiogenesis in postmenopausal patients.
Similar content being viewed by others
References
Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia.Nature 339: 58–61, 1989.
Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.Cell 64: 327–336, 1991.
Cross M, Dexter TM: Growth factors in development, transformation, and tumorigenesis.Cell 64: 271–280, 1991.
Senger DR, Galli SG, Dvorak AM,et al: Tumor cells secrets a vascular permeability factor that promotes accumulation of ascites fluids.Science 219: 983–985, 1983.
Leung DW, Cachianes G, Kuang W-J,et al: Vascular endothelial growth factor is a secreted angiogenic mitogen.Science 246: 1306–1309, 1989.
Gimbrone MA Jr, Leapman SB, Cotran RS,et al: Tumor dormancy in vivo by prevention of neovascu-larization.J Exp Med 136: 261–276, 1972.
Toi M, Hoshina S, Takayanagi T, Tominaga T: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer.Jpn J Cancer Res 85: 1045–1049, 1994.
Mattern J, Koomagi R, Volm M: Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma.Br J Cancer 73: 931–934, 1996.
Koide N, Nishio A, Hiraguri M,et al: Coexpression of vascular endothelial growth factor and p53 protein in squamous cell carcinoma of the esophagus.Am J Gastroenterol 96: 1733–1740, 2001.
Brown LF, Berse B, Jackman RW,et al: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.Cancer Res 53: 4727–4735, 1993.
Bosari S, Lee AK, DeLellis RA,et al: Microvessel quantitation and prognosis in invasive breast carcinoma.Hum Pathol 23: 755–761, 1992.
Gasparini G, Barbareschi M, Boracchi P,et al: Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.Cancer J Sci Am 1: 131, 1995.
Toi M, Kashitani J, Tominaga T: Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma.Int J Cancer 55: 371–374, 1993.
Eppenberger U, Kueng W, Schlaeppi JM,et al: Mark ers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.J Clin Oncol 16: 3129–3136, 1998.
Gasparini G, Toi M, Gion M,et al: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.J Natl Cancer Inst 89: 139–147, 1997.
Linderholm B, Tavelin B, Grankvist K, Henriksson R: Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma.J Clin Oncol 16: 3121–3128, 1998.
Linderholm B, Grankvist K, Wilking N, Johansson M, Tavelin B, Henriksson R: Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment.J Clin Oncol 18: 1423–1431, 2000.
Salven P, Perhoniemi V, Tykka H, Maenpaa H, Joen-suu H: Serum VEGF levels in women with a benign breast tumor or breast cancer.Breast Cancer Res Treat 53: 161–166, 1999.
Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, Pinedo HM: Platelet: transporter of vascular endothelial growth factor.Clin Cancer Res 3: 2187–2190, 1997.
Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Selby PJ: Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology.Br J Cancer 77: 956–964, 1998.
Webb NJ, Bottomley MJ, Watson CJ, Brenchley PE: Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease.Clin Sci 94: 395–404, 1998.
Adams J, Carder PJ, Downey S,et al: Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen.Cancer Res 60: 2898–2905, 2000.
Kieser A, Weich HA, Brandner G, Marine D, Kolch W: Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression.Oncogene 9: 963–969, 1994.
Silvestrini R, Benini E, Daidone MG,et al: p53 as an independent prognostic marker in lymph node-negative breast cancer patients.J Natl Cancer Inst 859: 65–70, 1993.
Bergh J, Norberg T, Sjogren S, Lindgren A, Holm-berg L: Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy.Nat Med 1: 1029–1034, 1995.
Borg A, Lennerstrand J, Stenmark-Askmalm M,et al: Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols.Br J Cancer 71: 1013–1017, 1995.
Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R: p53 and vascular-endothelial-growth- factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma.Int J Cancer 89: 51–62, 2000.
Nishimura R, Nagao K, Miyayama H,et al: An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer.Breast Cancer 9: 145–152, 2002.
Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, Klijn JG: High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer.Cancer Res 61: 5407–5414, 2001.
Chung HC, Rha SY, Ahn JB,et al: Menstrual state should be considered in determining sero-positivity of soluble angiogenic factors in breast cancer.Int J Mol Med 2: 465–470, 1998.
Greb RR, Maier I, Wallwiener D, Kiesel L: Vascular endothelial growth factor A (VEGF-A) mRNA expression levels decrease after menopause in normal breast tissue but not in breast cancer lesions.Br J Cancer 81: 225–231, 1999.
Agrawal R, Prelevic G, Conway GS, Payne NN, Gins-burg J, Jacobs HS: Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy.Fertil Steril 73: 56–60, 2000.
Schiffenbauer YS, Abramovitch R, Meir G,et al: Loss of ovarian function promotes angiogenesis in human ovarian carcinoma.Proc Natl Acad Sci USA 94: 13203–13208, 1997.
Blankenstein MA, van de Ven J, Maitimu-Smeele I,et al: Intratumoral levels of estrogens in breast cancer.J Steroid Biochem Mol Biol 69: 293–297, 1999.
Medri L, Nanni 0, Volpi A,et al: Tumor microvessel density and prognosis in node-negative breast cancer.Int J Cancer 89: 74–80, 2000.
Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, Bergh J: The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer.Cancer Res 61: 2256–2260, 2001.
Pinhasi-Kimhi O, Michalovitz D, Ben-Zeev A, Oren M: Specific interaction between the p53 cellular tumour antigen and major heat shock proteins.Nature 320: 182–184, 1986.
Levine AJ: Tumor suppressor genes.Bioassays 12: 60–66, 1990.
39) Bouvet M, Ellis LM, Nishizaki M, Fujiwara T, Liu W, Bucana CD, Fang B, Lee JJ, Roth JA: Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer.Cancer Res 58: 2288–2292, 1998.
Author information
Authors and Affiliations
Additional information
Reprint requests to Reiki Nishimura, Department of Surgery, Kumamoto City Hospital, 1-1-60 Kotoh, Kumamoto City, Kumamoto 862-8505, Japan.
About this article
Cite this article
Nishimura, R., Nagao, K., Miyayama, H. et al. Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer. Breast Cancer 10, 120–128 (2003). https://doi.org/10.1007/BF02967636
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02967636